Janux Therapeutics (JANX) PT Raised to $115 at Stifel

William Blair on Janux Therapeutics (JANX): 'Exceeding Investor Expectations and Raising the Bar in mCRPC'

December 3, 2024 7:06 AM EST

William Blair analyst Matt Phipps reiterated an Outperform rating on Janux Therapeutics (NASDAQ: JANX).

The analyst comments "On Monday, December 2, Janux disclosed updated clinical results with JANX007, the companys PSMAxCD3 TRACTr bispecific T-cell engager, in patients with heavily pretreated metastatic castrate resistant prostate cancer (mCRPC), demonstrating... More

Janux Therapeutics (JANX) PT Raised to $91 at Leerink Partners

December 3, 2024 6:55 AM EST

Leerink Partners analyst Jeffrey La Rosa raised the price target on Janux Therapeutics (NASDAQ: JANX) to $91.00 (from $79.00) while maintaining a Outperform rating.

The analyst comments "Bottom Line: Janux (JANX, OP) delivered with updated Ph 1 dose escalation data for lead candidate JANX007 (masked PSMA x... More

Janux Therapeutics (JANX) PT Raised to $70 at H.C. Wainwright

December 3, 2024 6:44 AM EST

(Updated - December 3, 2024 6:45 AM EST)

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Janux Therapeutics (NASDAQ: JANX) to $70.00 (from $63.00) while maintaining a Buy rating.

The analyst commented: "On December 2, Janux Therapeutics provided a clinical data update from the ongoing Phase 1 Study evaluating the PSMA-targeting tumor-activated T-cell engager (TRACTr), JANX007 to treat metastatic castration-resistant prostate cancer (mCRPC). Management reported data from 16 patients treated across a step-dosing regimen up to a target dose of 2, 3, 6 or 9 mg (Exhibit 1). PSA reduction of 50% from baseline was achieved in 100% (16/16) of treated patients, and PSA reduction of 90% and 99% from... More

Janux Therapeutics (JANX) PT Raised to $200 at Cantor Fitzgerald, 'Mic Drop - '007 HRPC Update Waaayyy Above Expectations'

December 3, 2024 6:23 AM EST

(Updated - December 3, 2024 6:32 AM EST)

Cantor Fitzgerald analyst Josh Schimmer raised the price target on Janux Therapeutics (NASDAQ: JANX) to $200.00 (from $100.00) while maintaining a Overweight rating.

The analyst comments "JANX reported much anticipated data for '007 (CD3 x PSMA masked TCE) for HRPC after the close. Results far exceeded the expectations we captured in an investor survey a few weeks back, and it looks... More

Janux Therapeutics (JANX) call put ratio 1 call to 2.8 puts into data

December 3, 2024 5:30 AM EST

Janux Therapeutics (NASDAQ: JANX) 30-day option implied volatility is at 160; compared to its 52-week range of 67 to 201 into Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC. Call put ratio 1 call to 2.8 puts.

... More

Stifel Reiterates Buy Rating on Janux Therapeutics (JANX)

December 3, 2024 5:27 AM EST

Stifel analyst Bradley Canino reiterated a Buy rating and $70.00 price target on Janux Therapeutics (NASDAQ: JANX).

The analyst comments "Updated ph.1a JANX007 (PSMA-TRACTr) ~5L mCRPC data at therapeutic weekly dose regimens suggest a potentially guaranteed biochemical PSA response pre-Pluvicto, with three-quarters lasting >12wks.... More

Janux Therapeutics (JANX) PT Raised to $100 at BTIG, 'The World Is Not Enough — 007 Strikes Again Exceeding The Street's Highest Expectations'

December 3, 2024 5:26 AM EST

BTIG analyst Justin Zelin raised the price target on Janux Therapeutics (NASDAQ: JANX) to $100.00 (from $82.00) while maintaining a Buy rating.

The analyst comments "Janux surpassed the street's high expectations with their eagerly anticipated data update today (see our preview note here). Heading into the data, we've heard investor concerns that expectations were too high for JANX to meet our bull case scenario of >60% PSA50 at 12-wks,... More

Vir Biotechnology (VIR) Trades Higher in Sympathy with Janux Therapeutics (JANX)

December 2, 2024 4:41 PM EST

Vir Biotechnology Inc. (NASDAQ: VIR) Trades Higher in Sympathy with Janux Therapeutics (NASDAQ: JANX)

Janux Therapeutics Surges 40% After Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC... More

Janux Therapeutics (JANX) Surges 40% After Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

December 2, 2024 4:40 PM EST

Janux Therapeutics (NASDAQ: JANX) Surges 40% After Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Emerging JANX007 data demonstrated substantial clinical activity in 5L mCRPC patients, supporting clinical development plan directed at pre-PLUVICTO® 2L / 3L patientsIn 16 patients... More

After-hours movers: Zscaler, Honeywell, Microchip Technology and more

December 2, 2024 4:38 PM EST

After-Hours Stock Movers:

Zscaler (NASDAQ: ZS) fell 6.5% despite topping consensus estimates for the first quarter of the year, after it issued guidance that was in-line with estimates.

Honeywell (NASDAQ:... More

Janux Therapeutics (JANX) Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

December 2, 2024 4:34 PM EST

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced positive updated interim clinical data for its JANX007 clinical program. Janux... More